Morphic to collaborate with Janssen to develop integrin therapeutics
Category: #health  By Mateen Dalal  Date: 2019-02-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Morphic to collaborate with Janssen to develop integrin therapeutics

Morphic has attained leadership position in the development of oral integrin inhibitors with the help of the ground-breaking structural research

Morphic Therapeutic, the Massachusetts-based biotechnology company recently announced that it has entered into a R&D collaboration with Janssen Biotech for the discovery and development of novel integrin therapeutics for patients whose medical issues are not sufficiently addressed by current therapies.

According to reliable sources, the transaction has been facilitated by Johnson & Johnson Innovation LLC. The collaboration will focus on several integrin targets and is expected to explore both activators and inhibitors of integrin function.

Morphic has attained leadership position in the development of oral integrin inhibitors with the help of the ground-breaking structural research conducted by Dr. Tim Springer, the founding scientist of Morphic Therapeutic. Applying this platform to all 24 recognized human integrins has potentially expanded the drug discovery abilities of Morphic as well as has extended its pipeline and taken therapeutic applications of Morphic drug candidates across a diverse set of disease which reflects the integrins’ significant role in many cellular processes.

Praveen Tipirneni, M.D., President and CEO, Morphic Therapeutic, has been reported to say that the Morphic team is pleased to have Janssen join its network of collaborators which would help it to develop a new generation of oral integrin medicines.

He added that the Morphic team’s mission is driven by the dysregulation of the diverse integrin family which is implicated in many conditions. The team is therefore systematically and rapidly interrogating this target class from an activation as well as inhibition perspective. The collaboration offers opportunities to improve oral integrin development into new extents of research which apparently creates value for all Morphic’s internal programs and speeds up the validation of its platform.

Under the terms of the agreement Morphic will receive multiple preclinical development from Janssen with clinical and commercial milestone payments amounting to $725 million on the achievements of milestones. Morphic is also slated to receive royalties on the basis of global net sales for products resulting from the partnership.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...